Twenty-year single-center experience with the medtronic open pivot mechanical heart valve.

BACKGROUND Since May 1992 the Medtronic Open Pivot mechanical heart valve has been implanted routinely at the authors' institution. The study aim was to analyze, retrospectively, the 20-year clinical results of the valve. METHODS Between May 1992 and December 2011 a total of 1,520 valves was inserted into 1,382 consecutive patients (1,012 aortic, 473 mitral, 26 tricuspid, 9 pulmonary). The mean age of the patients was 61±13.2 years. Preoperatively, 65% of the patients were in New York Heart Association (NYHA) class III or greater. Frequent comorbidities included atrial fibrillation (n=419), coronary disease (n=357), and diabetes (n=255). The 99% complete follow-up totaled 10,527 patient-years (range 12 to 244 months). RESULTS Ninety-day mortality was 5.2% (n=73, 8 valve related). Of the 550 total deaths, 240 were cardiac and 56 valve related. Multivariate analysis selected age, NYHA III or greater, concomitant coronary revascularization, and respiratory insufficiency as risk factors for death. Renal failure was considered a risk factor in the aortic and atrial fibrillation in the mitral subgroup. Erratic international normalized ratio (INR), NYHA class III or greater, and non-sinus rhythm were risk factors for thromboembolism; likewise redo operations in the aortic subgroup. Erratic INR and age were risk factors for bleeding as were over-coagulation and coronary revascularization in the aortic subgroup and redo operations and renal failure in mitral patients. CONCLUSIONS This 20-year experience demonstrated excellent clinical outcomes with no structural valve failure. Odds ratio defined aortic patients as the lowest risk for adverse events. By contrast atrial fibrillation and elderly age, in combination with instable anticoagulation, yielded the worst long-term results.

[1]  G. Tenderich,et al.  Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. , 2007, European heart journal.

[2]  C. Huynh,et al.  10-year experience with the ATS mechanical valve in the mitral position. , 2005, The Annals of thoracic surgery.

[3]  L. Grize,et al.  Single-center outcome analysis of 1,161 patients with St. Jude medical and ATS open pivot mechanical heart valves. , 2007, The Journal of heart valve disease.

[4]  P. Thompson,et al.  Surgical management of aortic valve disease in the elderly: A retrospective comparative study of valve choice using propensity score analysis. , 2008, The Journal of heart valve disease.

[5]  L. Menicanti,et al.  Aortic valve replacement in octogenarians: is biologic valve the unique solution? , 2008, The Annals of thoracic surgery.

[6]  J. Mayer,et al.  Guidelines for reporting mortality and morbidity after cardiac valve interventions. , 2008, The Annals of thoracic surgery.

[7]  Guidelines for reporting mortality and morbidity after cardiac valve interventions. , 2008, The Journal of thoracic and cardiovascular surgery.

[8]  M. Ruel,et al.  Long-term outcomes of valve replacement with modern prostheses in young adults. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  P. Kurlansky,et al.  The influence of coronary artery disease on quality of life after mechanical valve replacement. , 2004, The Journal of heart valve disease.

[10]  R. Emery,et al.  Anticoagulation for mechanical heart valves: a role for patient based therapy , 2008, Journal of Thrombosis and Thrombolysis.

[11]  L. Missault,et al.  Clinical experience with the first 100 ATS heart valve implants. , 1996, Cardiovascular surgery.

[12]  W. Ageno,et al.  Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study , 2012, American journal of hematology.

[13]  Kyung-Hwan Kim,et al.  Mechanical tricuspid valve replacement is not superior in patients younger than 65 years who need long-term anticoagulation. , 2012, The Annals of thoracic surgery.

[14]  J. Jacobs,et al.  Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. , 2012, The Annals of thoracic surgery.

[15]  R. Emery,et al.  The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. , 2005, The Annals of thoracic surgery.

[16]  D. Massel,et al.  Valve Disease Risks and Benefits of Adding AntiPlatelet Therapy to Warfarin Among Patients With Prosthetic Heart Valves : A Meta-Analysis , 2016 .

[17]  E. DeLong,et al.  Prediction of operative mortality after valve replacement surgery. , 2001, Journal of the American College of Cardiology.

[18]  R. Bergemann,et al.  Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. , 2005, Chest.

[19]  I. Park,et al.  Outcomes of mechanical valves in the pulmonic position in patients with congenital heart disease over a 20-year period. , 2013, The Annals of thoracic surgery.

[20]  Robert W Emery,et al.  The initial experience with the ATS Medical mechanical cardiac valve prosthesis. , 2003, The Annals of thoracic surgery.